NCT00112827View on ClinicalTrials.gov

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

February 15, 2019

Study Completion Date

February 15, 2019

Conditions
Refractory Multiple MyelomaSmoldering Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
RADIATION

total marrow irradiation

Undergo irradiation

DRUG

melphalan

Given IV

PROCEDURE

peripheral blood stem cell transplantation

Undergo transplantation

BIOLOGICAL

filgrastim

Given IV

GENETIC

fluorescence in situ hybridization

Correlative studies

GENETIC

cytogenetic analysis

Correlative studies

DRUG

cyclophosphamide

Given IV

PROCEDURE

autologous-autologous tandem hematopoietic stem cell transplantation

Undergo transplantation

DRUG

lenalidomide

Given orally

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT00112827 - Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter